CBD-CBDA Cannabinoid Composition for Anti-Inflammatory Immunosuppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutics for inflammatory conditions and autoimmune diseases, particularly TNF inhibitors, often fail to provide effective relief and can cause life-threatening responses, necessitating the development of alternative anti-inflammatory and immunosuppressant agents.

Innovation Solution

Cannabinoid compositions, particularly a 1:1 equimolar mixture of CBD:CBDA, and other specific cannabinoids, are formulated to act as anti-inflammatory and immunosuppressant agents, potentially inducing autophagy and reducing cytokine levels, with synergistic effects demonstrated in various assays.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If TNF inhibitors are used to treat inflammatory conditions, then anti-inflammatory effect is improved, but life-threatening responses occur

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidlife-threatening responses

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs a combination of cannabinoids (CBD and CBDA) as alternative therapeutic agents that can be administered repeatedly without the severe cumulative toxicity associated with TNF inhibitors. These compounds act as shorter-acting, replaceable therapeutics that avoid the life-threatening responses while maintaining anti-inflammatory efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent utilizes a composite approach by combining multiple cannabinoids (CBD and CBDA) in specific ratios to achieve synergistic anti-inflammatory effects. This composite therapeutic strategy distributes the therapeutic burden across multiple compounds, reducing the risk of severe adverse events compared to single-agent TNF inhibition.

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional synthetic DMARDs are used, then disease modification is achieved, but side effects increase

Engineering Contradiction:

Improvedisease modificationVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The cannabinoid compositions serve as alternative disease-modifying agents that can be administered without the severe and cumulative side effects characteristic of conventional synthetic DMARDs. The therapeutic compounds act as replaceable agents that maintain efficacy while reducing harmful long-term effects.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If corticosteroids are used, then anti-inflammatory effect is improved, but immunosuppression increases

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidimmunosuppression

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs cannabinoid compounds as alternative anti-inflammatory agents that provide therapeutic benefit without the profound and prolonged immunosuppression caused by corticosteroids. These compounds serve as shorter-acting alternatives that reduce inflammation while preserving immune function.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS20260000687A1Cannabinoid compositions and methods of using

Publication Date: 2026.01.01 GREENWAY HERBAL PRODUCTS LLC

AI summary

This disclosure describes compositions including cannabinoids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the pharmaceutical composition comprises an approximately 1:1 equimolar mixture of CBD:CBDA In other aspects, the pharmaceutical composition comprises a cannabinoid; and an approximately 1:1 equimolar mixture of CBD:CBDA. The composition may be substantially free of other cannabinoids.